Revolution MedicinesRVMD
About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Employees: 443
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
89% more call options, than puts
Call options by funds: $9.73M | Put options by funds: $5.15M
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
33% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 60
29% more funds holding in top 10
Funds holding in top 10: 14 [Q1] → 18 (+4) [Q2]
28% more capital invested
Capital invested by funds: $5.15B [Q1] → $6.58B (+$1.43B) [Q2]
7% more funds holding
Funds holding: 205 [Q1] → 220 (+15) [Q2]
5.76% more ownership
Funds ownership: 97.02% [Q1] → 102.78% (+5.76%) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Needham Ami Fadia 58% 1-year accuracy 73 / 125 met price target | 22%upside $61 | Buy Reiterated | 7 Oct 2024 |
Barclays Peter Lawson 44% 1-year accuracy 12 / 27 met price target | 20%upside $60 | Overweight Maintained | 27 Sept 2024 |
HC Wainwright & Co. Robert Burns 42% 1-year accuracy 54 / 128 met price target | 12%upside $56 | Buy Reiterated | 12 Aug 2024 |
JP Morgan Eric Joseph 54% 1-year accuracy 13 / 24 met price target | 8%upside $54 | Overweight Maintained | 8 Aug 2024 |
Wedbush Robert Driscoll 44% 1-year accuracy 26 / 59 met price target | 18%upside $59 | Outperform Reiterated | 8 Aug 2024 |